Lymphoblastic Lymphoma

Birgit Burkhardt; Birte Wistinghausen

doi:10.1007/978-3-030-11769-6_12

Lymphoblastic Lymphoma

Birgit Burkhardt, Birte Wistinghausen

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin, and 20-25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484-508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.

Original language	English
Title of host publication	Non-Hodgkin’s Lymphoma in Childhood and Adolescence
Publisher	Springer International Publishing
Pages	153-164
Number of pages	12
ISBN (Electronic)	9783030117696
ISBN (Print)	9783030117689
DOIs	https://doi.org/10.1007/978-3-030-11769-6_12
State	Published - 1 Jan 2019
Externally published	Yes

Keywords

Adolescents
Children
Lymphoblastic lymphoma
Precursor b cell
Precursor t cell

Access to Document

10.1007/978-3-030-11769-6_12

Cite this

@inbook{2cecadbe2b554c08ba965f58b4fde080,

title = "Lymphoblastic Lymphoma",

abstract = "Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin, and 20-25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484-508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.",

keywords = "Adolescents, Children, Lymphoblastic lymphoma, Precursor b cell, Precursor t cell",

author = "Birgit Burkhardt and Birte Wistinghausen",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2019.",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-3-030-11769-6_12",

language = "English",

isbn = "9783030117689",

pages = "153--164",

booktitle = "Non-Hodgkin{\textquoteright}s Lymphoma in Childhood and Adolescence",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Lymphoblastic Lymphoma

AU - Burkhardt, Birgit

AU - Wistinghausen, Birte

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2019.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin, and 20-25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484-508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.

AB - Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin, and 20-25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484-508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.

KW - Adolescents

KW - Children

KW - Lymphoblastic lymphoma

KW - Precursor b cell

KW - Precursor t cell

UR - http://www.scopus.com/inward/record.url?scp=85133998879&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-11769-6_12

DO - 10.1007/978-3-030-11769-6_12

M3 - Chapter

AN - SCOPUS:85133998879

SN - 9783030117689

SP - 153

EP - 164

BT - Non-Hodgkin’s Lymphoma in Childhood and Adolescence

PB - Springer International Publishing

ER -

Lymphoblastic Lymphoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this